Intelligent Bio Solutions Advances FDA Clearance for Drug Screening System

Event summary

  • Intelligent Bio Solutions completed its clinical Cut-off Study for codeine detection on schedule by the end of March 2026.
  • The study involved 40 adults and compared results with an FDA-cleared predicate device and LC-MS/MS analysis.
  • The company has initiated a second phase of clinical studies, including a Method Comparison and Usability Study, expected to complete by the end of June 2026.
  • An Interference Study is also underway, with completion anticipated by the end of July 2026.

The big picture

Intelligent Bio Solutions is targeting the multi-billion-dollar U.S. drug screening market with its non-invasive fingerprint technology. The successful completion of the Cut-off Study keeps the company on track for FDA clearance, positioning it to compete in segments like workplace testing, criminal justice, and substance abuse treatment. The technology's advantages, including rapid results and hygienic sample collection, could drive adoption in safety-critical industries.

What we're watching

Regulatory Timeline
Whether the company can maintain its schedule for FDA 510(k) submission and commercial launch.
Market Penetration
How the non-invasive fingerprint technology will compete with traditional drug screening methods.
Technical Validation
The outcomes of the Method Comparison and Interference Studies, which will be critical for market acceptance.

Related topics

Clinical Trial